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Background: This multi-centre phase II trial assessed the activity, safety (CTCAE 3.0) and pharmacokinetics (PK) of the
pan-Aurora kinase inhibitor danusertib hydrochloride (PHA-739358) in breast (BC), ovarian (OC), pancreatic (PC), colo-
rectal (CRC), small-cell (SCLC) and non-small-cell lung (NSCLC) cancers.
Methods: Consenting adult patients with good performance and organ function with advanced/metastatic tumours
who had failed systemic therapy were treated in independent, disease-specific cohorts with danusertib 500 mg/m2 given
as 24-h i.v. infusion every 14 days with until progression or unacceptable toxicity. A two-stage design was applied.
Primary end point was the progression-free rate (PFR) at 4 months (RECIST1.1).
Results: A total of 223 patients were enrolled with 219 actively treated. The median relative dose intensity of danusertib
was similar for all tumour types (84.6%–99.6%). The median number of biweekly treatment cycles ranged from 3 to
4/patient (maximum 5–40 cycles/entity) and the median treatment duration varied between 7.6 and 10.0 weeks per histo-
type. Danusertib did not meet pre-specified protocol criteria for clinically relevant activity in any of the treated cancers. The
PFR at 4 months was 18.4% in BC, 12.1% in OC, 10.0% in PC, 10.4% in NSCLC (all histotypes), 16.1% in squamous
NSCLC and 0% in SCLC and CRC. Some radiological and/or biochemical indication of antitumor activity was seen in BC,
OC, PC and NSCLC, including two confirmed partial responses. The most frequent drug-related non-laboratory adverse
events (AEs) were fatigue/asthenia, nausea, diarrhoea, anorexia, vomiting, alopecia, constipation and pyrexia. Common la-
boratory AEs included haematological toxicity, hypalbuminaemia and increases in liver enzymes. Treatment was discontin-
ued due to AEs in only 5.5% of patients. Plasma concentrations of danusertib were in line with results from earlier studies.
Conclusion: Single-agent danusertib did show only marginal anti-tumour activity in common solid tumours after failure of
prior systemic therapies. The safety and PK profile was consistent with previous experience.
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introduction
The Aurora kinases belong to a family of highly conserved serine/
threonine protein kinases. They play an essential role as key mitotic
regulators, controlling entry into mitosis, centrosome function,
chromosome assembly and segregation [1]. Three Aurora isoforms
are known in man [2]. Aurora kinase A is essential for the timely
entry into the M phase of the cell cycle, maintaining spindle bipo-
larity and chromosome segregation; Aurora kinase B is required
for chromosome condensation, alignment on the spindle, spindle
checkpoint function and cytokinesis. Little is known about the role
of Aurora kinase C. As many other regulators of mitosis, Aurora
kinases are frequently overexpressed in cancer cells. Therefore,
these proteins have become attractive targets for the development
of new anti-cancer therapies [3, 4].
Several small-molecule inhibitors of Aurora kinases have been
developed and some of them have shown clinical efficacy in phase
I and II clinical trials [5, 6]. Among those, one of the most
advanced compounds in the clinic is danusertib hydrochloride
(PHA-739358; Nerviano Medical Sciences, Nerviano, Italy),
which has inhibitory activity against all known Aurora kinases
[7–9]. Figure 1 illustrates the molecular structure of danusertib.
We carried out a multi-centric, multi-tumour phase II trial to
prospectively assess the anti-tumour activity of danusertib in
patients with breast (BC), ovarian (OC), pancreatic (PC), colo-
rectal (CRC), small-cell (SCLC) and non-small-cell lung
(NSCLC) cancer, including a NSCLC cohort selecting for squa-
mous cell carcinomas. Secondary end points of this study
included an evaluation of the safety profile of danusertib, the
monitoring of pharmacokinetics (PK) of the drug in plasma and
an exploratory assessment of gene expression profiles in tumour
biopsies with potential use for response prediction and patient
selection in future trials. The latter results will be reported in a
separate publication.
patients andmethods
study design
This prospective phase II, open-label study was conducted at 22 investiga-
tional sites in 7 European countries and carried out in accordance with the
Declaration of Helsinki, the ICH Harmonised Tripartite Guideline for Good
Clinical Practice and national regulatory requirements. All patients provided
written informed consent. Patients received danusertib, which was provided
by the study sponsor, Nerviano Medical Sciences S.r.l. (Nerviano, Italy).
Adult patients with progressive, locally advanced and/or metastatic BC,
OC, CRC, PC, SCLC or NSCLC who had failed second to third lines of pal-
liative treatment as defined per tumour type, were treated with danusertib as
a 24-h i.v. infusion every 14 days at a starting dose of 500 mg/m2, based on
results of a phase I trial [10]. The protocol allowed a dose escalation for
patients without relevant toxicity in the first treatment cycle and dose reduc-
tions in case of adverse events (AEs) during treatment.
For each independent tumour type, a Simon’s two-stage design was
applied, allowing early termination at completion of the first stage in case of
low activity of danusertib in a given tumour type. The primary end point of
the study was the progression-free rate (PFR) at 4 months, i.e. the proportion
of patients who were still alive and had not progressed during the first
4 months from treatment start. Patients were followed for AEs from informed
consent until 28 days after the last dose of study treatment or until a new anti-
cancer therapy was started. Safety assessments (vital signs, haematology, blood
chemistry and urinalysis) were carried out at baseline, at pre-defined time
points during the treatment period and at the end of the experimental treat-
ment. Electrocardiogram (ECG) monitoring and QT interval/corrected QT
(QTC) interval assessment were done at baseline, in cycles 1 and 2, and at the
end of treatment. A transthoracic echocardiogram or multi-gated acquisition
scan were scheduled at the baseline visit and at the end of treatment, to
monitor the left ventricular ejection fraction (LVEF).
The RECIST 1.1 efficacy assessment [11] was primarily based on computed
tomography (CT) and X-ray investigations; magnetic resonance imaging and
positron emission tomography were optional. Imaging was carried out at base-
line (within 21 days before the initial infusion treatment) and repeated every 2
calendar months during treatment, with a mandatory scan at the 4 months
visit. CT scans of patients with squamous NSCLC were peer-reviewed. Serial
tumour marker assessments included the evaluation of CA 125, CEA and CA
19-9, depending on the histological entity, and were done at the same time
points as the imaging studies. The safety assessment was based on vital signs,
laboratory parameters and cardiac function tests and used CTCAE version 3.0.
Plasma samples were collected before the start of the infusion and just
before (5–10 min) the end of infusion on day 1 of treatment cycles 1, 2, 4
and 8 for PK purposes. Danusertib and its N-oxide metabolite PHA-816359
were assessed in plasma using a validated LC-MS/MS method [12, 13]. As
exploratory end points protein and gene expression were assessed in pre-
and post-treatment tumour biopsies in a subset of selected NSCLC patients.
Results of this analysis will be reported in a separate publication.
A Simon’s two-stage design was used per tumour type to determine
whether danusertib had sufficient activity to warrant further clinical testing
[14]. The two-stage procedure allowed the early termination of a given inde-
pendent disease-specific cohort in case of low activity of the experimental
compound. The design was based on testing the null hypothesis, H0: P≤ p0,
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Figure 1. Molecular structure of danusertib.
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that the true PFR at 4 months was less than or equal to some uninteresting
level p0, against the alternative hypothesis that the true PFR achieved at least
some desirable target level p1. At first stage, the Simon design aimed at stop-
ping the trial if the alternative hypothesis, H1: P≥ p1, could be rejected. In
this trial, α and β were defined as 0.1. Table 1 presents for each independent
tumour type the p0 and p1 assumptions, the required number of assessable
patients to be recruited at each stage and the critical number of responses to
proceed to the second stage and to reject the null hypothesis. For each
tumour type, the median PFR retrieved from literature was used to estimate
the PFR at 4 months under the null hypothesis. The computation was done
assuming an exponential distribution of the survival function (i.e. constant
hazard rate over time). Based on these assumptions, the numbers of patient
treated/assessable for each tumour type were the following: 42/38 patients
for BC, 34/33 for OC, 33/28 for CRC, 36/30 PC, 18/12 for SCLC and 56/48
for NSCLC. PFR was assessed per disease-specific cohort at the end of each
of the two steps of the trial. Point estimates were presented along with two-
tail 95% confidence intervals (95% CIs). Summary descriptive statistics
including range and median values were estimated according to the Kaplan–
Meier method for time-related. Descriptive statistical analyses and individual
data listings were produced for the analysis of patient disposition, protocol
deviations, baseline characteristics and safety data.
Nerviano Medical Sciences S.r.l. sponsored this trial and provided finan-
cial support. All authors contributed to data collection, analysis or interpret-
ation. PS was responsible for drafting, editing and finalizing the manuscript,
with input provided by all authors.
results
patient population and tumour characteristics
A total of 223 patients were enrolled in this trial and 219
patients were treated. Table 2 summarizes the characteristics of
the enrolled population. Four entered patients, one with CRC,
one with PC and two with NSCLC, were never treated. The vast
majority of patients (93.6%) had metastatic disease. The most
frequent sites of metastasis were lymph nodes and liver and the
majority of patients had two disease recurrences/progressions
before entering the study. The mean age at study entry was 59.2
years, and most patients (92.2%) were Caucasian. Female
patients were slightly overrepresented (59.8%), and there were
an equal number of patients with Eastern Cooperative Oncology
Group (ECOG) performance status 0 or 1 in this trial (47.9%
and 51.1%, respectively).
danusertib treatment
The median absolute and relative dose intensity of danusertib
were similar for all tumour types, ranging from 211.4 to 249.1
mg/m2/week and from 84.6% to 99.6%, respectively. The
median number of biweekly treatment cycles delivered ranged
from 3 to 4 per patient with a maximum ranging from 5 to 40
courses, depending on the tumour type. Treatment modifica-
tions consisted mainly in dosing delays and infusions not com-
pleted as per protocol. The most frequent reasons for dose
delays were haematological toxicity and logistic reasons. Only
seven patients were treated with the allowed increased dose of
580 mg/m2 after completing the first cycle. The most frequent
reason for treatment discontinuation was disease progression
(189 patients, 86%); treatment was discontinued due to AEs in
only 5.5% of patients.
treatment efficacy
Danusertib did not meet protocol criteria to conclude for clinic-
ally relevant activity in any of the tumour types investigated in
this trial. In BC, 7 of 38 assessable patients were free from
Table 1. Assumption of the Simon’s two-stage design for this trial
Tumour type
α = 0.1 β = 0.1 BC OC PC CRC SCLC NSCLC
3rd line 3rd line 2nd line 3rd line 2nd line 2nd line
Median time of PFS for p0 (months) 1.7 2.8 2.3 2.0 1.7 1.7
PFR at 4 months according to p0 (%) 20 37 30 25 20 20
PFR at 4 months according to p1 (%) 40 57 50 44 40 40
Median time of PFS for p1 (months) 3.0 5.0 4.0 3.4 3.0 3.0
n1 19 24 28 22 19 19
r1 3 9 7 5 3 3
n 36 42 39 43 36 36
R 10 19 15 14 10 10
(r + 1)/n (%) 30.5 47.6 41.0 34.9 30.5 30.5
The study design was based on testing a null hypothesis, H0: P≤ p0, that the true progression-free rate (PFR) at 4 months was less than or equal to
some uninteresting level p0, against an alternative one that the true PFR achieved at least some desirable target level p1. At first stage, Simon’s design
aimed at stopping the trial if the alternative hypothesis, H1: P≥ p1, could be rejected. In this trial, α and β were taken both equal to 0.1 and the
following table presents, for each tumour type, the parameters p0 and p1 (tumour type distinctive) used in the set of hypotheses, the required number of
assessable patients to be recruited at each stage and the critical number of responses to proceed to second stage and to reject null hypothesis at second
and final stage. For each tumour type, the median progression-free rate (PFR) retrieved from literature was used to estimate the PFR at 4 months under
the null hypothesis. The computation was done assuming an exponential distribution of the survival function (i.e. constant hazard rate over time).
PFS, progression-free survival; PFR, progression-free rate; p0, uninteresting level of activity; p1, interesting level of activity; n1, first-stage sample size of
assessable patients; r1, upper limit for first-stage rejection of drug; n, maximum sample size of assessable patients; r, upper limit for second-stage
rejection of drug; (r + 1)/n, lowest percentage of progression-free patients at 4 months by which p0 is rejected at the end of second stage.
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Table 2. Patient and tumour characteristics and treatment history
Tumour type BC (N = 42) OC (N = 34) CRC (N = 33) PC (N = 36) SCLC (N = 18) NSCLC (N = 56) All (N = 219)
Age (years)
Mean 53.2 59.0 60.5 59.8 60.7 62.2 59.2
Range 36–70 35–76 38–77 39–80 49–75 39–79 35–80
<65 years 40 23 24 24 13 36 160
≥65 years 2 11 9 12 5 20 59
Sex
M/F 0/42 0/34 23/10 16/20 12/6 37/19 88/131
Race
Caucasian/othera 39/3 34/0 32/1 35/1 13/5 49/7 202/17
Performance status
0 23 19 21 13 9 20 105
1 19 15 12 21 9 36 112
2 0 0 0 2 0 0 2
Tumour type BC (N = 42) OC (N = 34) CRC (N = 33) PC (N = 36) SCLC
(N = 18)
NSCLC
(N = 56)
All
(N = 223)
n % n % n % n % n % n % n %
Extent of disease
Metastatic 42 100 32 94.1 33 100 34 94.4 17 94.4 47 83.9 205 93.6
Locally advanced – – 2 5.9 – – 2 5.6 1 5.6 9 16.1 14 6.4
Sites of metastases
Bone 26 61.9 1 2.9 6 18.2 3 8.3 6 33.3 9 16.1 51 23.3
Liver 23 54.8 7 20.6 27 81.8 25 69.4 8 44.4 15 26.8 105 47.9
Lung 14 33.3 5 14.7 22 66.7 12 33.3 2 11.1 24 42.9 79 36.1
Lymph nodes 15 35.7 26 76.5 17 51.5 13 36.1 13 72.2 34 60.7 118 53.9
Other 10 23.8 23 67.6 8 24.2 11 30.6 6 33.3 19 33.9 76 34.7
No. of recurrences
1 – – 1 2.9 1 3 25 69.4 13 72.2 33 58.9 73 33.3
2 8 19.0 25 73.5 18 54.5 10 27.8 5 27.8 19 33.9 85 38.8
>2 34 81.0 8 23.5 14 42.4 1 2.8 – – 4 7.1 61 27.9
Time from primary diagnosis to treatment start (months)
Median 76.3 21.2 24 8.1 10.1 11.7 17.5
Range 9.2–226.7 8.2–163.8 5.6–91.2 3.0–31.8 4.4–41.3 3.2–46.8 3.0–226.7
Time from current diagnosis of advanced/metastatic to treatment start (months)
Median 25.5 15.0 17.3 6.0 9.8 7.9 11.3
Range 3.3–121.1 0.0–34.5 1.1–55.9 0.5–20.6 0.7–41.3 0.2–36.6 0.0–121.1
No. of prior therapies
At least 1 42 100 34 100 33 100 36 100 18 100 56 100 219 100
Type of prior therapies
Systemic – – 1 2.9 3 9.1 16 44.4 3 16.7 20 35.7 43 19.6
Systemic + surgery 5 11.9 31 91.2 21 63.6 17 47.2 – – 6 10.7 80 36.5
Systemic + radiotherapy 2 4.8 – – 2 6.1 – – 14 77.8 20 35.7 38 17.4
Systemic + surgery + radiotherapy 35 83.3 2 5.9 7 21.2 3 8.3 1 5.6 10 17.9 58 26.5
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progression after 4 months of treatment, when compared with
the 11 (or more) of 36 required at the end of the second stage to
reject the null hypothesis. In OC, 4 of 33 assessable patients
were free from progression after 4 months of treatment, when
compared with the 10 (or more) of 24 required at the end of the
first stage not to reject the alternative hypothesis and to proceed
with the second stage. In PC, 3 of 30 assessable patients were
free from progression at 4 months precluding the move to the
second stage. In CRC, all 28 treated patients assessable for effi-
cacy progressed before the end of the 4th month. In SCLC, none
of the assessable patients was free from progression at the
month 4 assessment. In non-selected NSCLC patients, the PFR
at month 4, observed at the completion of the first stage, did not
meet the protocol criteria to proceed with the second stage. In
NSCLC selected for squamous cell histology, the PFR at month 4,
met the protocol criteria to proceed with the second stage (i.e. at
least 3 of 19 assessable patients free from progression at month
4). In the second stage, 5 of 31 assessable patients with squa-
mous histology were free from progression at 4 months.
In the total study population, confirmed RECIST partial
responses were limited to one patient with OC (total treatment
duration 12 weeks) and one patient with squamous NSCLC
(treatment duration 24 weeks). Key efficacy data obtained in this
trial are summarized in Table 3. Biochemical responses, here
defined as a longitudinal decrease in serum tumour markers
>50% when compared with baseline, were seen in three patients
with OC, in one patient with PC, in three patients with CRC
and in one patient with NSCLC.
safety of danusertib
Overall 219 patients were treated and were assessable for safety.
Among these, 216 of patients (98.6%) experienced at least one
AE in the first or subsequent cycles. No obvious differences in
toxicity were observed among tumour types. The most frequent
treatment-related non-haematological AEs (frequency of ≥10%)
were fatigue/asthenia (62.1% of patients), nausea (42.0%), diar-
rhoea (35.2%), anorexia (23.3%), vomiting (21.5%), alopecia
(20.5%), constipation (18.3%) and pyrexia (10%).
Neutropenia was the most common haematological toxicity
(94.4%) as well as the most frequent grade 3–4 event (82.9%)
followed by anaemia, reported in 64.1% of patients. Febrile neu-
tropenia and neutropenic sepsis were documented in 17 (7.8%)
and 3 (1.4%) of the 219 treated patients.
Non-haematological laboratory abnormalities were less fre-
quent than haematological events and mainly restricted to mild-
to-moderate elevations of liver enzymes. Serum aspartate trans-
aminase and serum alanine transaminase increased in 28.4%
and 31.6% of patients, respectively, with grade 3–4 increases in
only 3.3% and 3.7% of cases. An increase in alkaline phosphat-
ase was reported in 38.1% of patients (2.8%, grade 3–4), and
hyperbilirubinaemia was observed in 11.2% of cases (2.3%
grade 3–4).
Drug-related grade 3–4 events occurred in 80 patients (36.5%)
and included fatigue/asthenia (28 cases, 12.8%), febrile neutro-
penia (17 cases, 7.8%), neutropenia (9 cases, 4.1%), anaemia (9
cases, 4.1%), diarrhoea (8 cases, 3.7%), leucopenia (5 cases, 2.3%),
neutropenic sepsis (3 cases, 1.4%), chest pain, pyrexia, abdominal
pain, urinary tract infection, anorexia, hypertension and transami-
nases increased (2 cases each, 0.9%), febrile bone marrow aplasia,
extravasation, lethargy, mucosal inflammation, abdominal pain
upper, dysphagia, vomiting, infection, hypophosphataemia,
jugular vein thrombosis, thrombosis, venous thrombosis of the
limb, hepatic disorder and function abnormal, headache, pruritus
and rash erythematous (1 case each, 0.5%). Hypertension (transi-
ent, asymptomatic, reversible, mostly of grade 1–2 in severity) was
reported as being drug related in 14 patients (6.6%).
During treatment, no clinically relevant abnormalities in ECG
tracing were observed. Ten patients had ECG tracing alterations
reported as clinical AE, but only two of these events were con-
sidered related to study treatment (namely, grade 1 sinus tachy-
cardia and two episodes of grade 2 atrial flutter in NSCLC
Table 3. Efficacy of danusertib per tumour type—assessable patients
Tumour type BC (N = 38) OC (N = 33) CRC (N = 28) PC (N = 30) SCLC (N = 14) NSCLC all (N = 48) NSCLC squamous
(N = 31)
Progression-free rate at 4 months (primary end point)
No. of patients 7 4 0 3 0 5a 5a
% 18.4 12.1 0 10.0 0 10.4 16.1
95% CI (%) 7.7–34.3 3.4–28.2 0.0–12.3 2.1–26.5 3.5–22.7 5.5–33.7
Confirmed partial response (RECIST)
No. of patients 0 1 0 0 0 1a 1a
Median progression-free survival
Weeks 8.3 9.3 7.9 8.0 8.1 9.2 9.0
95% CI (weeks) 7.6–9.1 8.7–10.0 7.6–8.9 7.1–9.1 7.1–8.9 18.1–16.6 7.3–16.3
Median overall survival
Months 12.0 9.8 8.8 4.0 11.4 7.6 7.6
95% CI (months) 9.3–16.1 6.1–14.3 6.0–12.3 2.5–8.6 4.5–n.r. 6.0–10.3 5.6–10.4
50% decrease in serum tumour marker CEA, CA 19-9 or CA 125
No. of patients 0 3 3 1 0 0 0
aSame patient.
n.r., not related.
 | Schöffski et al. Volume 26 | No. 3 | March 2015
original articles Annals of Oncology
 at K
U
 Leuven U
niversity Library on M
arch 16, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
patients). Only two patients in the treated trial population had a
QTc interval prolongation, and only two patients had a docu-
mented LVEF decrease ≥10% when compared with baseline.
None of these observed cardiac function alterations were consid-
ered clinically relevant.
In the clinical database, 167 serious adverse events (SAEs)
have been recorded in 99 treated patients and 61 (36.5%) of
these SAEs, which occurred in 43 patients, were considered as
related to the study treatment. Overall, 21 deaths on study (i.e.
occurring from patient’s consent up to 28 days after last treat-
ment dose) were reported. All events with fatal outcome were
assessed by the Investigators as unrelated to the study drug
except for two patients who died due to bacterial sepsis and
septic shock, both categorized as unlikely being related to the
study drug. No grade 5 drug-related events were reported.
Almost all patients died due to progression of the underlying
cancer or due to events related to their cancer.
The AE profile of danusertib in this multi-tumour phase II
trial was similar to safety and tolerability findings in previously
reported studies with this agent. Key safety parameters of our
trial are summarized in Tables 4, 5 and 6.
pharmacokinetics of danusertib and PHA-816359
Plasma concentrations of danusertib and PHA-816359 were
determined in 195 of 219 treated patients. After each cycle of
treatment end infusion concentration (Cendinf ) values of PHA-
739358 were comparable among patients with different tumour
types while trough concentrations of danusertib were highly
variable due to the closeness of the concentrations to the lower
Table 4. Treatment emergent adverse events possibly to definitely related to study treatment occurring in ≥10% of treated patients—all grades, all
cycles
Event BC
(N = 42)
OC
(N = 34)
CRC
(N = 33)
PC
(N = 36)
SCLC
(N = 18)
NSCLC
(N = 56)
All
(N = 219)
n % n % n % n % n % n % n %
Any term 39 92.9 34 100.0 27 81.8 32 88.9 15 83.3 49 87.5 196 89.5
Fatigue/asthenia 32 76.2 25 73.5 11 33.3 19 38.9 11 61.1 38 67.9 136 62.1
Nausea 21 50.0 23 67.6 5 15.2 14 38.9 7 38.9 22 39.3 92 42.0
Diarrhoea NOS 18 42.9 15 44.1 12 36.4 13 36.1 3 16.7 16 28.6 77 35.2
Anorexia 8 19.0 7 20.6 6 18.2 11 30.6 3 16.7 16 28.6 51 23.3
Vomiting NOS 9 21.4 12 35.3 5 15.2 8 22.2 4 22.2 9 16.1 47 21.5
Alopecia 13 31.0 8 23.5 3 9.1 7 19.4 1 5.6 13 23.2 45 20.5
Constipation 9 21.4 14 41.2 3 9.1 4 11.1 4 22.2 6 10.7 40 18.3
Anaemia NOS/haemoglobin decreased 6 14.3 10 29.4 3 9.1 9 25.0 2 11.1 7 12.5 37 16.9
Pyrexia 6 14.3 7 20.6 2 6.1 3 8.3 – – 4 7.1 22 10.0
NOS, not otherwise specified.
Table 5. Haematology toxicity—worst CTC grade emerged or worsened on treatment by patient-treated patients with at least one assessment
on treatment
CTC grade BC
(N = 42)
OC
(N = 34)
CRC
(N = 33)
PC
(N = 36)
SCLC
(N = 18)
NSCLC
(N = 56)
All
(N = 219)
n % n % n % n % n % n % n %
Haemoglobin N 42 100.0 34 100.0 32 100.0 35 100.0 18 100.0 56 100.0 217 100.0
1–4 28 66.7 27 79.4 15 46.9 19 54.3 13 72.2 37 66.1 139 64.1
3–4 2 4.8 1 2.9 – – 3 8.6 – – 5 8.9 11 5.1
Platelet count N 42 100.0 34 100.0 32 100.0 35 100.0 18 100.0 56 100.0 217 100.0
1–4 4 9.5 4 11.8 – – 4 11.4 – – 4 7.1 16 7.4
3–4 1 2.4 – – – – – – – – 1 1.8 2 0.9
WBC N 42 100.0 34 100.0 32 100.0 35 100.0 18 100.0 56 100.0 217 100.0
1–4 41 97.6 30 88.2 30 93.8 31 88.6 16 88.9 52 92.9 200 92.2
3–4 25 59.5 23 67.6 21 65.6 13 37.1 14 77.8 31 55.4 127 58.5
Neutrophils N 42 100.0 34 100.0 32 100.0 35 100.0 18 100.0 55 100.0 216 100.0
1–4 42 100.0 32 94.1 29 90.6 32 91.4 16 88.9 53 96.4 204 94.4
3–4 36 85.7 30 88.2 29 90.6 27 77.1 16 88.9 41 74.5 179 82.9
Lymphocytes N 42 100.0 34 100.0 30 100.0 35 100.0 18 100.0 55 100.0 214 100.0
1–4 26 61.9 22 64.7 14 46.7 23 65.7 10 55.6 36 65.5 131 61.2
3–4 5 11.9 2 5.9 2 6.7 10 28.6 5 27.8 9 16.4 33 15.4
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limit of quantification value. After repeated cycles of treatment,
the accumulation ratio of PHA-739358 Cendinf was in the range
0.830–0.917 in BC, 1.00–1.42 in OC, 0.824–1.17 in PC, 0.496–
1.07 in CRC, 0.796–1.75 in SCLC and 0.871–1.82 in NSCLC
patients. Throughout the cycles of treatment, metabolite to
parent Cendinf ratios were, on average, 0.509, 0.812, 0.460, 0.630,
0.325 and 0.305 in BC, OC, PC, CRC, SCLC and NSCLC
patients, respectively. No difference on end infusion concentra-
tion of danusertib was apparent among patients with different
tumour types. Apart from the higher PHA-739358 Cendinf terms
of the accumulation ratio range in SCLC (1.75) and NSCLC
(1.82) patients, metabolite to parent ratio was similar among
patients and approximately equal to 1, indicating, overall, no
relevant accumulation of the maximal concentrations of the
compound after repeated cycles of treatment. Throughout cycles
of treatment, as overall mean, the levels of the metabolite
accounted for 50% than those of the parent compound. Cycle 1
concentrations at end infusion of danusertib were similar to that
one (mean ± SD: 3.20 ± 1.29 μM) obtained in a previous PK
study. Table 7 summarizes the mean ± standard deviation
plasma Cendinf and trough concentrations of treatment cycles 1,
2, 4 and 8.
discussion
This multi-centric, multi-tumour phase II trial assessed the effi-
cacy and safety of the pan-Aurora kinase inhibitor danusertib in
independent cohorts of solid tumour patients after failure of
second to third lines of systemic treatment. The ‘basket’ design
of this trial allowed the assessment of activity of the experimen-
tal compound simultaneously in several independent disease-
specific entities in a very efficient manner.
The safety profile observed was consistent with previous
experience with the drug in patients with other solid tumours.
No new toxicities were reported and the main target was the
haematopoietic system in all tumour subtypes. Neutropenia
was the most frequent toxicity (94.4%) as well as the most fre-
quent cause of grade 3–4 toxicities (82.9%). Anaemia and
Table 6. Blood chemistry toxicity—worst CTC grade emerged or worsened on treatment by patient-treated patients with at least one assessment
on treatment
CTC grade BC
(N = 42)
OC
(N = 34)
CRC
(N = 33)
PC
(N = 36)
SCLC
(N = 18)
NSCLC
(N = 56)
All
(N = 219)
n % n % n % n % n % n % n %
Albumin N 41 100.0 34 100.0 32 100.0 32 100.0 15 100.0 54 100.0 208 100.0
1–4 17 41.5 20 58.8 7 21.9 18 56.3 8 53.3 20 37.0 90 43.3
3–4 – – 1 2.9 – – 1 3.1 – – 1 1.9 3 1.4
Alkaline phosphatase (ALP) N 42 100.0 34 100.0 32 100.0 33 100.0 18 100.0 56 100.0 215 100.0
1–4 16 38.1 12 35.3 11 34.4 19 57.6 6 33.3 18 32.1 82 38.1
3–4 1 2.4 2 5.9 1 3.1 2 6.1 – – – – 6 2.8
AST/GOT N 42 100.0 34 100.0 32 100.0 33 100.0 18 100.0 56 100.0 215 100.0
1–4 14 33.3 10 29.4 11 34.4 12 36.4 4 22.2 10 17.9 61 28.4
3–4 2 4.8 1 2.9 1 3.1 2 6.1 – – 1 1.8 7 3.3
ALT/GPT N 42 100.0 34 100.0 32 100.0 33 100.0 18 100.0 56 100.0 215 100.0
1–4 16 38.1 8 23.5 9 28.1 14 42.4 6 33.3 15 26.8 68 31.6
3–4 – – 1 2.9 2 6.3 3 9.1 – – 2 3.6 8 3.7
Bilirubin total N 42 100.0 34 100.0 32 100.0 33 100.0 18 100.0 56 100.0 215 100.0
1–4 4 9.5 3 8.8 6 18.8 6 18.2 1 5.6 4 7.1 24 11.2
3–4 1 2.4 – – – – 3 9.1 – – 1 1.8 5 2.3
Creatinine N 42 100.0 34 100.0 33 100.0 33 100.0 18 100.0 56 100.0 216 100.0
1–4 3 7.1 5 14.7 1 3.0 4 12.1 3 16.7 4 7.1 20 9.3
Uric acid N 41 100.0 34 100.0 31 100.0 32 100.0 18 100.0 56 100.0 212 100.0
1–4 4 9.8 7 20.6 4 12.9 5 15.6 4 22.2 7 12.5 31 14.6
3–4 – – – – – – 1 3.1 – – – – 1 0.5
Calcium N 42 100.0 34 100.0 33 100.0 33 100.0 18 100.0 56 100.0 216 100.0
1–4 12 28.6 12 35.3 10 30.3 11 33.3 6 33.3 18 32.1 69 31.9
3–4 1 2.4 1 2.9 – – – – – – 1 1.8 3 1.4
Phosphorus, inorganic N 41 100.0 34 100.0 31 100.0 31 100.0 15 100.0 53 100.0 205 100.0
1–4 8 19.5 8 23.5 7 22.6 6 19.4 4 26.7 20 37.7 53 25.9
3–4 2 4.9 1 2.9 2 6.5 2 6.5 1 6.7 7 13.2 15 7.3
Potassium N 42 100.0 34 100.0 33 100.0 33 100.0 18 100.0 56 100.0 216 100.0
1–4 8 19.0 12 35.3 7 21.2 8 24.2 2 11.1 14 25.0 51 23.6
3–4 – – 1 2.9 – – – – – – 1 1.8 2 0.9
Sodium N 42 100.0 34 100.0 33 100.0 33 100.0 18 100.0 56 100.0 216 100.0
1–4 9 21.4 12 35.3 10 30.3 14 42.4 8 44.4 28 50.0 81 37.5
3–4 1 2.4 1 2.9 3 9.1 4 12.1 2 11.1 4 7.1 15 6.9
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thrombocytopenia, mostly of grade 1–2, were reported only oc-
casionally. Fatigue/asthenia, mainly grade1–2 in severity, was
the most frequent drug-related AE in all tumour types, with the
highest frequency in BC and OC patients (76.2% and 73.5%, re-
spectively), followed by NSCLC and SCLC (67.9% and 61.1%).
Grade 3–4 fatigue/asthenia was uncommon. Mild-to-moderate
gastrointestinal AEs were more frequently observed in OC
(94.1%) and in BC patients (73.8%), ranging from 51.1% to
63.9% in the other tumour categories tested. The relative
absence of effects of the pan-Aurora kinase inhibitor on cardiac
function and QTc, and the absence of treatment-related deaths
among 219 patients treated in this trial are favourable features of
danusertib when compared with other experimental treatments.
PK findings of this trial confirmed the previous experience
with danusertib PK in patients with solid tumours. Regarding
the maximum concentrations of the compound in plasma after
repeated cycles of treatment, the drug was found not to accumu-
late. Throughout treatment, the levels of the metabolite PHA-
739358 accounted for about 50% of the concentrations of the
parent compound.
Unfortunately, danusertib monotherapy did not meet proto-
col criteria to conclude for clinically relevant activity in any of
the tumour categories investigated. The number of assessable
patients free from progression after 4 months of treatment
remained below the threshold defined by protocol. The chosen
cut-offs in this trial were based on a thorough analysis of activity
of reference treatments in patients with these common cancer
types.
There was some indication of clinical activity in patients with
NSCLC, OC, PC and BC, with two confirmed objective RECIST
responses, some patients with significant decreases in relevant
serum tumour markers and a subset of trial participants who
remained stable on active treatment of multiple consecutive
cycles of i.v. danusertib. In fact, the proportion of patients
remaining on active experimental treatment beyond 6, 12 and
24 weeks was 72%, 24% and 9%, respectively.
The unfavourable anti-tumour activity of danusertib observed
in this multi-tumour trial is in line with the experience with
this and similar cell-cycle modulating agents in oncology.
Danusertib showed only marginal activity in solid tumour
patients [10, 15] during phase I dose finding, and minimal effi-
cacy in a randomized phase II study in patients with castration-
resistant prostate cancer [22]. AT9283, a potent inhibitor of
Aurora kinases A and B, achieved only one objective response
during phase I dose finding [16]. In a paediatric dose finding
trial, the Aurora kinase A inhibitor alisertib achieved an anec-
dotal partial response in a child with hepatoblastoma. In adult
patients with gynaecological malignancies, three patients with
platinum-resistant OC achieved objective responses with that
compound [17]. Other Aurora kinase inhibitors that were
studied in early clinical trials have failed to induce objective
responses, such as in the case of the phase I trial with barasetib
in solid tumour patients [18].
Not surprisingly, more promising results have been obtained
with this haematotoxic class of anti-cancer compounds in
patients with haematological malignancies, especially in the case
of more promiscuous, multi-targeted Aurora-inhibiting agents
and Aurora kinase inhibitors used in combination with cyto-
toxic agents. The multi-targeted inhibitor MK-0457, that also
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inhibits Aurora, was found to be active in BCR-ABL T315I-
mutated chronic myelogenous leukaemia, with haematological
responses in eight patients, and in three further patients with
Philadelphia chromosome-positive acute lymphoblastic leukae-
mia [19]. When prospectively assessed in a haematological
phase I study, MSC1992371A, an oral inhibitor of Aurora and
other kinases, induced complete responses in two patients with
secondary acute myelogenous leukaemia and in one patient
with chronic myeloid leukaemia [20].
In combination with cytarabine, the selective Aurora kinase B
inhibitor barasertib achieved an International Working Group
Criteria response rate of 45% in haematological tumours [21].
Based on the current clinical experience with various Aurora
kinase inhibitors including danusertib, it is unlikely that such
promising results in leukaemia can also be obtained in unse-
lected patients with refractory solid tumours after failure of sys-
temic chemotherapy, as tested in the current study.
conclusions
Single-agent danusertib was well tolerated and had favourable
PK properties, but showed only marginal anti-tumour activity
in heavily pre-treated patients with common advanced solid
tumours. Future trials with cell-cycle modulating agents should
involve mandatory sequential tissue sampling in all trial partici-
pants with accessible lesions and an extensive assessment of bio-
markers, to facilitate the identification of predictive factors that
could be used for patient selection.
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